Allmed Medical(SZ:002950)2025-06-12 10:48Group 1: Financial Performance - The company has distributed a total cash dividend of approximately 1.099 billion yuan from 2018 to 2024, which is 2.29 times the net amount of funds raised [3][5] - In 2024, the company achieved overseas revenue of 2.756 billion yuan, a year-on-year increase of 23.43%, accounting for 82.87% of total revenue [3][4] - Domestic revenue reached 569.79 million yuan in 2024, up 8.86% year-on-year, representing 17.13% of total revenue [4] Group 2: Market Strategy - The company has implemented a dual-drive strategy focusing on both domestic and international markets to increase market share [5][6] - The company has maintained its position as the leading exporter in China's medical dressing industry for 17 consecutive years since 2008 [3][7] - Future focus areas include expanding product lines in surgical and wound care, infection prevention, advanced dressings, and hygiene care products [6][7] Group 3: Challenges and Outlook - The company acknowledges that stock price fluctuations are influenced by various factors, emphasizing the importance of long-term value creation for shareholders [5][6] - Recent reductions in cash dividends are attributed to strategic upgrades and planned investments in emerging markets and product development [6] - The company aims to enhance brand influence and market share in the domestic market through e-commerce and professional hospital channels [4][6]